S&P 500   3,957.63
DOW   33,852.53
QQQ   280.57
Three Reasons It’s Time To Get Bullish On Organigram
The Safest Option in Trades! (Ad)pixel
The AP Interview: IMF head urges China to end mass lockdowns
Survivor of Virginia Walmart mass shooting files $50M suit
The Safest Option in Trades! (Ad)pixel
Can I Apply for Supplemental Security Income Online?
US stocks edge lower in unsteady trading, oil prices rise
The Safest Option in Trades! (Ad)pixel
Why Investors Are Eating Up Restaurant Brands International
Opportunity Strikes! Hibbett, Inc Falls Flat On Strong Results
S&P 500   3,957.63
DOW   33,852.53
QQQ   280.57
Three Reasons It’s Time To Get Bullish On Organigram
The Safest Option in Trades! (Ad)pixel
The AP Interview: IMF head urges China to end mass lockdowns
Survivor of Virginia Walmart mass shooting files $50M suit
The Safest Option in Trades! (Ad)pixel
Can I Apply for Supplemental Security Income Online?
US stocks edge lower in unsteady trading, oil prices rise
The Safest Option in Trades! (Ad)pixel
Why Investors Are Eating Up Restaurant Brands International
Opportunity Strikes! Hibbett, Inc Falls Flat On Strong Results
S&P 500   3,957.63
DOW   33,852.53
QQQ   280.57
Three Reasons It’s Time To Get Bullish On Organigram
The Safest Option in Trades! (Ad)pixel
The AP Interview: IMF head urges China to end mass lockdowns
Survivor of Virginia Walmart mass shooting files $50M suit
The Safest Option in Trades! (Ad)pixel
Can I Apply for Supplemental Security Income Online?
US stocks edge lower in unsteady trading, oil prices rise
The Safest Option in Trades! (Ad)pixel
Why Investors Are Eating Up Restaurant Brands International
Opportunity Strikes! Hibbett, Inc Falls Flat On Strong Results
S&P 500   3,957.63
DOW   33,852.53
QQQ   280.57
Three Reasons It’s Time To Get Bullish On Organigram
The Safest Option in Trades! (Ad)pixel
The AP Interview: IMF head urges China to end mass lockdowns
Survivor of Virginia Walmart mass shooting files $50M suit
The Safest Option in Trades! (Ad)pixel
Can I Apply for Supplemental Security Income Online?
US stocks edge lower in unsteady trading, oil prices rise
The Safest Option in Trades! (Ad)pixel
Why Investors Are Eating Up Restaurant Brands International
Opportunity Strikes! Hibbett, Inc Falls Flat On Strong Results
NASDAQ:TRVI

Trevi Therapeutics - TRVI Stock Forecast, Price & News

$1.89
-0.02 (-1.05%)
(As of 11/29/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.86
$2.02
50-Day Range
$1.54
$2.21
52-Week Range
$0.46
$4.68
Volume
42,259 shs
Average Volume
61,677 shs
Market Capitalization
$113.25 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.25

Trevi Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
336.5% Upside
$8.25 Price Target
Short Interest
Healthy
0.48% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.00mentions of Trevi Therapeutics in the last 14 days
Based on 10 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.53) to ($0.54) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.11 out of 5 stars

Medical Sector

597th out of 1,038 stocks

Pharmaceutical Preparations Industry

290th out of 510 stocks

TRVI stock logo

About Trevi Therapeutics (NASDAQ:TRVI) Stock

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

Receive TRVI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Trevi Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TRVI Stock News Headlines

/C O R R E C T I O N -- Trevi Therapeutics, Inc./
Trevi Therapeutics Announces Proposed Public Offering
Trevi Therapeutics: Moving Forward
See More Headlines
Receive TRVI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Trevi Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TRVI Company Calendar

Last Earnings
11/10/2022
Today
11/30/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/16/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TRVI
Fax
N/A
Employees
24
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$8.25
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+336.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-33,940,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.83 per share

Miscellaneous

Free Float
36,241,000
Market Cap
$113.25 million
Optionable
Not Optionable
Beta
0.75

Key Executives

  • Ms. Jennifer L. Good (Age 57)
    Co-Founder, CEO, Pres & Director
    Comp: $731.41k
  • Dr. Thomas R. Sciascia M.D. (Age 69)
    Co-Founder & Chief Science Officer
    Comp: $499.65k
  • Ms. Lisa Delfini (Age 52)
    Chief Financial Officer
  • Mr. Christopher Galletta (Age 44)
    Controller & Chief Accounting Officer
  • Katie McManus
    Communications Mang.
  • Mr. Farrell Simon Pharm.D.
    Sr. VP and Head of Commercial & Strategy
  • Dr. David J. Clark A.F.P.M. (Age 57)
    M.D., M.R.C.P., Chief Medical Officer
  • Ms. Danine Summers (Age 64)
    VP of Medical Affairs













TRVI Stock - Frequently Asked Questions

Should I buy or sell Trevi Therapeutics stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Trevi Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TRVI shares.
View TRVI analyst ratings
or view top-rated stocks.

What is Trevi Therapeutics' stock price forecast for 2023?

4 Wall Street analysts have issued 12 month target prices for Trevi Therapeutics' stock. Their TRVI share price forecasts range from $6.00 to $10.00. On average, they predict the company's stock price to reach $8.25 in the next twelve months. This suggests a possible upside of 336.5% from the stock's current price.
View analysts price targets for TRVI
or view top-rated stocks among Wall Street analysts.

How have TRVI shares performed in 2022?

Trevi Therapeutics' stock was trading at $0.7822 at the beginning of 2022. Since then, TRVI shares have increased by 141.6% and is now trading at $1.89.
View the best growth stocks for 2022 here
.

When is Trevi Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 16th 2023.
View our TRVI earnings forecast
.

How were Trevi Therapeutics' earnings last quarter?

Trevi Therapeutics, Inc. (NASDAQ:TRVI) announced its earnings results on Thursday, November, 10th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.03.

What other stocks do shareholders of Trevi Therapeutics own?
When did Trevi Therapeutics IPO?

(TRVI) raised $70 million in an IPO on Tuesday, May 7th 2019. The company issued 4,700,000 shares at a price of $14.00-$16.00 per share. SVB Leerink, Stifel and BMO Capital Markets served as the underwriters for the IPO and Needham & Company was co-manager.

What is Trevi Therapeutics' stock symbol?

Trevi Therapeutics trades on the NASDAQ under the ticker symbol "TRVI."

Who are Trevi Therapeutics' major shareholders?

Trevi Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Fairmount Funds Management LLC (12.93%), Rubric Capital Management LP (12.90%), Vanguard Group Inc. (3.01%), Altium Capital Management LP (2.42%), Silverarc Capital Management LLC (2.13%) and Armistice Capital LLC (1.96%). Insiders that own company stock include Enterprise Associates 16 New, Paul Edward Walker and Tpg Gp A, Llc.
View institutional ownership trends
.

How do I buy shares of Trevi Therapeutics?

Shares of TRVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Trevi Therapeutics' stock price today?

One share of TRVI stock can currently be purchased for approximately $1.89.

How much money does Trevi Therapeutics make?

Trevi Therapeutics (NASDAQ:TRVI) has a market capitalization of $113.25 million. The company earns $-33,940,000.00 in net income (profit) each year or ($0.78) on an earnings per share basis.

How can I contact Trevi Therapeutics?

Trevi Therapeutics' mailing address is 195 CHURCH STREET 14TH FLOOR, NEW HAVEN CT, 06510. The official website for the company is www.trevitherapeutics.com. The company can be reached via phone at (203) 304-2499 or via email at peter.vozzo@westwicke.com.

This page (NASDAQ:TRVI) was last updated on 11/30/2022 by MarketBeat.com Staff